Navigation Links
UPM Signs Joint Development Agreement with Renmatix in Biochemicals

HELSINKI, June 11, 2013 /PRNewswire/ -- UPM (OMX: UPM1V) and Renmatix, Inc., have entered into a non-exclusive joint development agreement (JDA) in the area of biochemicals. Under terms of the JDA both companies will further develop Renmatix's water-based Plantrose™ process to convert woody biomass into low-cost sugar intermediates for subsequent downstream processing into biochemicals. Offering cost-competitive bio-alternatives for select petrochemicals on an industrial scale is the long term goal of this initiative.

"We are very excited about this truly collaborative endeavor. It combines UPM's core competencies in sustainable sourcing and efficient industrial processing of wood, with Renmatix's unique conversion technology," noted Michael Duetsch, Director of Biochemicals, at UPM. "Access to second generation, lignocellulosic, sugars through a process that uses almost no consumables is a crucial factor in Plantrose technology's attractiveness."

The Plantrose process employs water at very high temperatures and pressures to breakdown biomass through supercritical hydrolysis. Under such conditions water can act as both a powerful solvent and catalyst, creating rapid reactions.

"We believe this pioneering approach leads to real cost advantages over conventional methods. Our growing relationship with UPM gives Renmatix an opportunity to support them expanding the Biofore story," commented Mike Hamilton, CEO of Renmatix. "Renmatix, as a U.S. based technology provider, takes great pride in working with global companies across the emerging bio-value chains. It reinforces the demand that exists for licensing Plantrose technology as the bridge between sustainable sources of upstream biomass, and downstream manufacturing of biochemicals and fuels."

"The joint development agreement with Renmatix is another milestone in the implementation of our biochemicals strategy and UPM's Biofore vision. The co-operation further strengthens our position as the frontrunner in the innovation-driven integration of bio and forest industries," adds Juuso Konttinen, Vice President of UPM.

UPM leads the integration of bio and forest industries into a new, sustainable and innovation-driven future. Our products are made of renewable raw materials and are recyclable. UPM consists of three Business Groups: Energy and pulp, Paper, and Engineered materials. The Group employs around 22,000 people. UPM is present in 67 countries and has production units in 17 countries. UPM's annual sales exceed EUR 10 billion. UPM's shares are listed on the Helsinki stock exchange. UPM – The Biofore Company –

UPM New Businesses and Development (NBD) is an important part of UPM's renewal and Biofore strategy. The objective of NBD is to provide added value to renewable wood raw material by developing ideas into new products and businesses. The key projects are biocomposites, biofibrils and biochemicals.

Renmatix is the leading manufacturer of cellulosic sugar, an enabling feedstock for petroleum alternatives used in the global biochemical and biofuels markets. The company's proprietary Plantrose™ process challenges conventional sugar economics by cheaply converting cellulosic biomass – from wood waste to agricultural residue – into useful, cost-effective sugars. Renmatix's supercritical hydrolysis technology deconstructs non-food biomass an order of magnitude faster than other processes and enhances its cost advantage by using no significant consumables. Renmatix is privately held, with operations in Georgia (USA) currently capable of converting three dry tons of cellulosic biomass to Plantro® sugar per day, and a world-class technical center in Pennsylvania (USA).

For further information, please contact:
Michael Duetsch, Director, Biochemicals, UPM, +49.821.310.9130 (German, English)
Juuso Konttinen, Vice President, New Businesses & Development, UPM, +358.40.531.7405 (Finnish, English)
Duncan Cross, Director, Marketing, Renmatix, +484.751.4000 (English, French)
Tim Brown, Vice President, Corporate Strategy, Renmatix,

UPM, Corporate Communications
Media Desk, +358.40.588.3284

Renmatix, Media Inquiries
Katie Struble, +415.977.1928

SOURCE Renmatix
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Elsevier Signs Strategic Collaboration Agreement with Peoples Medical Publishing House, China
2. Alexandrias 499 Illinois Street in Mission Bay, San Francisco, Signs Anchor 97,700 Rentable Square Foot Lease with Leading Mid-Cap Life Science Company
3. Australian Distributor of Express Diagnostics Signs Sponsorship Agreement with V8 Supercar Team
4. Phosphagenics Signs Research Agreement with the Agricultural Research Service
5. Adaptive Biotechnologies Signs Biomarker Discovery Collaboration Agreement with Bristol-Myers Squibb
6. Vestiage Signs Buyside Engagement Agreement with CJK Securities
7. Vertilon Signs Crisel Instruments as its Distributor in Italy
8. Bausch + Lomb Signs Exclusive License Agreement with Paragon BioTeck for Phenylephrine
9. Entertainment Agency and Speaker Bureau Mark Sonder Productions Signs the Health & Wellness Shaman, Robert Cohen, PhD, LPC, DCEP for Meetings and Events Worldwide
10. Samsung Thales signs Development Agreement with Novelda
11. Eddie Leong Signs on as Advisory Board Member and Compliance Officer for Grace Century, International Research and Private Equity Consultant
Post Your Comments:
(Date:11/27/2015)... ... November 27, 2015 , ... Pittcon is pleased to ... presentations offered in symposia, oral sessions, workshops, awards, and posters. The core ... of applications such as, but not limited to, biotechnology, biomedical, drug discovery, environmental, ...
(Date:11/25/2015)... November 26, 2015 ... Market 2016 - 2020 report analyzes that automating ... and quality in long-term samples, minimizing manual errors, ... Automation minimizes manual errors such as mislabeling or ... Further, it plays a vital role in blood ...
(Date:11/25/2015)... and HOLLISTON, Mass. , Nov. ... (Nasdaq: HART ), a biotechnology company developing bioengineered ... Jim McGorry will present at the LD ... 2015 at 2:30 p.m. PT. The presentation will be ... 30 days. Management will also be available at the ...
(Date:11/25/2015)... -- Orexigen® Therapeutics, Inc. (Nasdaq: OREX ) today ... discussion at the Piper Jaffray 27th Annual Healthcare Conference ... is scheduled for Wednesday, December 2, at 8:00 a.m. ... will be available for 14 days after the event.  ... Corporate Communications and Business Development , BrewLife(858) 875-8629 ...
Breaking Biology Technology:
(Date:11/11/2015)... Minn. , Nov. 11, 2015   MedNet Solutions ... entire spectrum of clinical research, is pleased to announce that ... in Clinical Trials (PCT) event, to be held November ... be able to view live demonstrations of iMedNet ... and learn how iMedNet has been able to ...
(Date:11/9/2015)... DUBLIN , Nov. 09, 2015 /PRNewswire/ ... announced the addition of the "Global ... to their offering. --> ... "Global Law Enforcement Biometrics Market 2015-2019" ... Research and Markets ( ) ...
(Date:11/2/2015)... PARK, Calif. , Nov. 2, 2015  SRI ... $9 million to provide preclinical development services to the ... the contract, SRI will provide scientific expertise, modern testing ... wide variety of preclinical pharmacology and toxicology studies to ... --> The PREVENT Cancer Drug Development ...
Breaking Biology News(10 mins):